Drug Profile


Alternative Names: Allogeneic ex-vivo expanded placental adherent stromal cells; PLacental eXpanded cells; PLX-PAD cell therapy

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pluristem Therapeutics
  • Class Ischaemic heart disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell differentiation modulators; Cell replacements; Dendritic cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia; Thromboangiitis obliterans
  • New Molecular Entity No

Highest Development Phases

  • Phase III Peripheral arterial disorders
  • Phase II Intermittent claudication; Muscle injury
  • Preclinical Duchenne muscular dystrophy; Graft-versus-host disease
  • No development reported Ischaemic heart disorders; Preeclampsia; Pulmonary arterial hypertension; Tendon injuries

Most Recent Events

  • 15 Jun 2018 9243048 - Updated introduction, KDM, TT and AE data.
  • 13 Jun 2018 European Medicines Agency (EMA) clears a phase III trial in Critical limb ischaemia
  • 13 Jun 2018 Efficacy and adverse events from a phase II trial in Intermittent claudication released by Pluristem Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top